P
P

Pfizer


Hírek

Wall Street Journal - Sept 27

Sept 27 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. - Pfizer Inc PFE.N and BioNTech SE 22UAy.DE asked U.S. health regulators to clear use of their updated Covid-19 booster in children 5 years to 11 years. - Ford Motor Co F.N is asking a Georgia court for a new trial, after a jury reached a $1.7 billion verdict against the auto maker last month involving a truck rollover accident that left
B
P
T

UK Stocks-Factors to watch on Sept 20

Sept 20 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher on Tuesday, with futures FFIc1 up 0.57%. * HALEON: Haleon HLN.L said it had notified GSK GSK.L and Pfizer PFE.N that it had rejected their requests for indemnification in relation to U.S.-based litigation over the heartburn drug, Zantac. * FULLER: Fuller, Smith & Turner FSTA.L warned that the global energy crisis would significantly raise its expected full-year costs for gas and electricity.
G
K
P
T
U

Pfizer donates Paxlovid to group targeting COVID in poorer countries

By Jennifer Rigby LONDON, Sept 7 (Reuters) - Pfizer PFE.N has donated 100,000 courses of its COVID-19 antiviral treatment Paxlovid to a new group aiming to improve access to the drug in low and middle-income countries. The Covid Treatment Quick Start Consortium, set up by organizations including Duke University and the Clinton Health Access Initiative with support from the pharmaceutical company, said it is working with ministries of health in 10 countries to set up national test-and-treat progr
P

Ukraine's Zelenskiy 'rings' NYSE bell, seeks $400 bln in foreign investment

* Zelenskiy opens New York market after meeting JPM, Pfizer * Ukraine seeks $400 billion for 500 projects * 'Advantage Ukraine' focuses on pharma, energy, military By Andrea Shalal KYIV/NEW YORK, Sept 6 (Reuters) - Ukraine's President Volodymyr Zelenskiy remotely rang the opening bell at the New York Stock Exchange on Tuesday as his nation appealed for billions of dollars in private investment to rebuild factories and industries destroyed by Russia.
J
P
W

Ukraine launches platform to attract private sector investments as war rages

By Andrea Shalal KYIV/NEW YORK, Sept 6 (Reuters) - Ukrainian Economy Minister Yulia Svyrydenko on Tuesday launched a new platform listing over 500 investment projects worth $400 billion and appealed to foreign investors to help rebuild the country's economy, even as the war with Russia drags on. The announcement was made as Ukraine's President Volodymyr Zelenskiy rang the opening bell at the New York Stock Exchange on Tuesday, after a roundtable with top executives from JP Morgan, Pfizer Inc and
J
P

UK Stocks-Factors to watch on Sept 5

Sept 5 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening lower, with futures FFIc1 down 0.9% on Monday. * ASTON MARTIN: British luxury carmaker Aston Martin AML.L confirmed a 575.8 million pound ($659.8 million) rights issue, with backing from investors including Saudi Arabia's sovereign wealth fund. *SMMT: British new car registrations rose about 1% in August from a year earlier, according to preliminary industry data released by the Society of Motor Manufacturers and Traders (SMMT).
P
U

UK Stocks-Factors to watch on Sept 5

Sept 5 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening lower, with futures FFIc1 down 0.9% on Monday. * COUNTRYSIDE: British builders Countryside Partnerships CSPC.L and Vistry Group VTYV.L are nearing a deal to form a $3.2 billion residential developer, suggesting a win for U.S.-based activist fund Browning West, the Wall Street Journal reported on Sunday.
P
U

Financial Times - Sept 2

Sept 2 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines - UK government wins pension fund legal challenge over change to RPI Link - Starbucks taps head of Reckitt Benckiser as its new CEO Link - Limit on profits of low-carbon generators in sights of new UK prime minister Link - EU drug regulator recommends approval of COVID vaccine boosters for Omicron Link Overview - The UK government ha
P
S

Wall Street Journal - Sept. 1

Sept 1 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. - Bed Bath & Beyond Inc BBBY.O said it would close roughly 20% of its namesake stores, cut its workforce and bring in fresh cash to stabilize the business through the holiday season as it confronts plunging sales.
B
P
T

Wall Street Journal - Aug 23

Aug 23 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. - Elon Musk's lawyers have sent a subpoena to Jack Dorsey, the first indication that Twitter Inc's TWTR.N co-founder and former chief executive will be officially involved in the legal fight over Musk's stalled $44 billion deal.
P

UK first to approve Omicron COVID shot with Moderna nod

* UK's JCVI backs using bivalent shot in autumn booster campaign * Moderna sees Australia, Canada, EU approvals soon By Natalie Grover LONDON, Aug 15 (Reuters) - Britain, the first country to approve a coronavirus vaccine in late 2020, has now also given the first green light to a variant-adapted shot that targets both the original and Omicron version of the virus.
A
G
P
S

Haleon not a party to U.S. litigation focused on Zantac - spokesperson

By Natalie Grover LONDON, Aug 11 (Reuters) - Haleon - GSK's recently spun off consumer health unit - is not a party to U.S. litigation focused on the heartburn medicine Zantac, a spokesperson told Reuters on Thursday. "We have never marketed Zantac in any form in the U.S., as Haleon or as GSK consumer healthcare," the spokesperson said, responding to Reuters querying a near-20% decline in Haleon's share price this week.
G
P
S

Wall Street Journal - August 9

Aug 9 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. - As Kewsong Lee's five-year contract was drawing to a close, advisers to Carlyle Group Inc's CG.O CEO worked with representatives of the buyout firm to prepare an initial proposal for a new deal but the contract proposal never got a response from Carlyle's board.
B
P
A

Biden again tests positive for 19, feels 'quite well' - White House

(Recasts top) By Jarrett Renshaw and Pete Schroeder WASHINGTON, July 30 (Reuters) - U.S. President Joe Biden tested positive for COVID-19 again on Saturday morning in what the White House doctor describes as a "rebound" case seen in a small percentage of patients who take the antiviral drug Paxlovid. Biden, 79, who emerged from COVID isolation on Wednesday after testing positive on July 21, will now return to strict isolation and will cancel planned trips to his home in Wilmington and work trip
P

New York Times business news - July 29

July 29 (Reuters) - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy. - Instagram META.O said it was rolling back several recent updates to its photo-sharing app after Kylie Jenner and other celebrities joined a user backlash against the changes and criticized the platform for trying to be too much like TikTok.
P

Financial Times - July 22

July 22 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines - Pfizer and Flynn fined 70 mln stg by UK regulator for epilepsy drug price rises Link - EDF pushes UK government to alter Hinkley Point C penalty clauses Link - Tata threatens to close Port Talbot steelworks without 1.5 bln stg of aid Link - Marks and Spencer finance chief to depart retailer and join Primark owner ABF Link Overview
E
M
P
A

British Business - July 22

July 22 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times - The European Central Bank has raised its benchmark interest rate for the first time in more than a decade with a rise of 50 basis points to 0%. Link - EDF EDF.PA is seeking to amend the controversial subsidy contract for its 26 billion pounds ($31.17 billion) Hinkley Point C nuclear plant so that it will not b
E
G
H
P

What are benefits and risks of Paxlovid to treat Biden's COVID?

(Updates headline with no further changes to text) By Julie Steenhuysen July 21 (Reuters) - Here is a rundown of possible treatments U.S. President Joe Biden will receive for COVID-19 and the risks he faces, having been infected most likely with the fast-spreading but less severe BA.5 variant. TREATMENTS At 79, the president falls into a high risk category for COVID but has the advantage of medical advances that improve his chances for a full recovery.
P

Adapted, two-strain vaccines to lift COVID protection - EU official

FRANKFURT/LONDON, July 13 (Reuters) - Adapted versions of established mRNA COVID-19 vaccines that address two variants in one shot will soon offer people better protection than vaccines that are now available, a European health official said on Wednesday. Moderna MRNA.O and the BioNTech-Pfizer 22UAy.DE PFE.N alliance are working on vaccines based on a combination of the original Wuhan virus and an Omicron subvariant.
P

Adapted, two-strain vaccines to lift COVID protection - EU official

FRANKFURT, July 13 (Reuters) - A European health emergency official on Wednesday said adapted versions of established mRNA COVID-19 vaccines that address two variants in one shot will soon offer people better protection than vaccines that are now available. Moderna MRNA.O and the BioNTech-Pfizer 22UAy.DE PFE.N alliance are working on vaccines based on a combination of the original Wuhan virus and an Omicron subvariant.
P



Feltételek

Népszerű eszközök

Felelősségkizáró nyilatkozat: Az XM Group entitásai csak végrehajtási szolgáltatást és online kereskedési platformunkhoz való hozzáférést biztosítanak, ami lehetővé teszi, hogy a felhasználók megtekinthessék és/vagy felhasználhassák a honlapon vagy azon keresztül elérhető tartalmakat, amelyek nem módosíthatók és nem egészíthetők ki. A hozzáférés és felhasználás mindig a következők függvénye: (i) Felhasználási feltételek; (ii) Kockázati figyelmeztetés; valamint (iii) Teljes felelősségkizáró nyilatkozat. Az ilyen tartalmakat ezért csupán általános információként biztosítjuk. Külön felhívjuk figyelmét arra, hogy az online kereskedési platformunkon található tartalmak nem felhívások vagy ajánlatok tranzakciókba történő belépésre a pénzügyi piacokon. A pénzügyi piacokon folytatott kereskedés jelentős kockázattal jár a tőkéjére nézve.

Az online kereskedési platformunkon közzétett anyagok kizárólag oktatási / tájékoztatási célt szolgálnak, és nem tartalmaznak (nem tekinthető úgy, hogy tartalmaznak) pénzügyi, befektetési adóügyi vagy kereskedési tanácsokat vagy ajánlásokat, illetve kereskedési áraink jegyzékét, vagy bármilyen pénzügyi instrumentummal végrehajtott tranzakcióra vonatkozó ajánlatot vagy felhívást, vagy Önnek szóló kéretlen pénzügyi promóciókat.

Az ezen a honlapon szereplő, külső felektől származó, valamint az XM által készített tartalmak, például vélemények, hírek, kutatások, elemzések, árak és egyéb információk vagy külső felek oldalaira utaló hivatkozások „jelenlegi állapotukban”, általános piaci magyarázatként jelennek meg, és nem minősülnek befektetési tanácsnak. Amennyiben bármely tartalom befektetéssel kapcsolatos kutatásként értelmezhető, meg kell értenie és el kell fogadnia, hogy a tartalom nem a befektetéssel kapcsolatos kutatás függetlenségének előmozdítására szolgáló jogi követelmények szerint készült, következésképpen a vonatkozó törvények és jogszabályok szerint marketingkommunikációnak minősül. Kérjük, feltétlenül olvassa el és értse meg a fenti információkkal kapcsolatos „nem független befektetéskutatással kalcsolatos tájékoztatónkat” és a kockázati figyelmeztetésünket, amelyek itt érhetők el.

Honlapunkon a legjobb felhasználói élmény biztosítása érdekében sütiket használunk. Tájékozódjon a részletekről, vagy módosítsa süti beállításait.

Kockázati figyelmeztetés: a tőkeáttételes termékekkel folytatott kereskedés jelentős kockázatnak teszi ki befektetett tőkéjét, és nem feltétlenül megfelelő minden befektető számára. Kérjük, olvassa el a kockázati figyelmeztetés erre vonatkozó részleteit.